Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Keros Therapeutics Inc. (KROS:NASDAQ), powered by AI.
Keros Therapeutics Inc. is currently trading at $10.03. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Keros Therapeutics Inc. on Alpha Lenz.
View Keros Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Keros Therapeutics Inc.'s ROE is 19.9%. Explore profitability and growth together.”
Ask for details →Keros Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of groundbreaking treatments for hematological and musculoskeletal disorders. The company's primary aim is to address unmet medical needs by advancing innovative therapies that target the transforming growth factor-beta (TGF-beta) family of proteins. These proteins play a critical role in the regulation of cellular growth and development, making them pivotal in treating a variety of severe diseases. Keros Therapeutics is deeply involved in research and development, with a strong pipeline of drug candidates aimed at conditions such as anemia and other blood-related disorders, as well as muscle diseases that impact patient mobility. By targeting these specific biological pathways, Keros is contributing significantly to the biopharmaceutical industry’s efforts in developing more effective and personalized medicine. The company's operations are an important part of the healthcare sector, striving to deliver breakthroughs that can enhance the quality of life for patients worldwide.
“Keros Therapeutics Inc.'s ROE is 19.9%. Explore profitability and growth together.”
Ask for details →Keros Therapeutics Inc. (ticker: KROS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 148 employees.
The current price is $10.03 with a P/E ratio of -x and P/B of -x.
ROE is 19.90% and operating margin is 27.69%. Annual revenue is $244M.